Background: Egypt has one of the highest (16-8%) prevalence rates of HCV infection in the world. Approximately 90% of Egyptian HCV isolates belong to a single subtype (4a), which responds less successfully to interferon therapy than other subtypes. Studies comparing the efficacy and safety of PEGIFN alfa-2a and PEGIFN alfa-2b in treatment-naive HCV-infected patients have shown conflicting results.
Objectives: Assessing the effects of Peginterferon alpha-2a versus Peginterferon alpha-2b on the sustained virological response in naive chronic HCV genotype-4 Egyptian patients.
Patients And Methods: This retrospective study cohort consists of 3718 chronic HCV patients admitted to a large, Egyptian medical center. 1985 patients had been treated with PEG-IFN alfa-2a plus RBV and 1733 patients with PEG-IFN alfa-2b plus RBV between years 2007-2011. Efficacy outcomes were sustained virologic response (SVR) and treatment discontinuation rates due to serious adverse effects.
Results: The ETR & SVR in patients treated with PEGIFN alfa-2a was 64.1% and 59.6% as compared to treatment with PEGIFN alfa-2b where these parameters were 58.2% and 53.9% respectively (P < 0.05). Treatment discontinuation rates, were similar in the two types of PEGIFN [0.66 (0.37-1.16); P = 0.15]. Significant dose reduction was evident with peginterferon alfa-2b (35.3%) than peginterferon alpha-2a (27.3 %) (P < 0.01). Patients with lower base line AFP and ALT were most likely to achieve SVR using INF alpha 2-a.
Conclusions: Peginterferon alpha-2a has a higher efficacy regarding ETR and SVR as compared to Peginterferon alfa-2b in treatment of naive chronic HCV genotype-4 patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732660 | PMC |
| http://dx.doi.org/10.5812/hepatmon.10069 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study.
Lancet Gastroenterol Hepatol
December 2024
Department of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Article Synopsis
- Chronic hepatitis B virus (HBV) is a significant global health concern, with existing treatments yielding low rates of HBsAg seroclearance; VIR-2218 (elebsiran) is being studied for its potential to reduce HBsAg levels.
- This phase 2 open-label study involved participants aged 18-65 from various countries who had chronic HBV but no cirrhosis, assessing the safety and effectiveness of VIR-2218 alone and in combination with pegylated interferon-alpha-2a.
- The study aimed to measure adverse events and clinical outcomes, including the reduction of HBsAg and long-term seroclearance rates among those receiving different treatment regimens over a period ranging from
Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patients.
J Dtsch Dermatol Ges
November 2024
Department of Dermatology and Venereology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Article Synopsis
- Interferon-alpha is crucial for treating cutaneous T-cell lymphomas (CTCL), but the approved version (IFN-α2a) has been unavailable since January 2020, prompting the use of pegylated interferon-α2a (pegIFN-α2a), which is not officially approved for this condition.
- A study involving 70 CTCL patients from twelve German skin centers found a 55.2% overall response rate to pegIFN-α2a, with common adverse effects leading to a 50% discontinuation rate within about 63 weeks.
- The findings suggest that pegIFN-α2a therapy may have similar efficacy and side effects as the discontinued IF
HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B.
Gut
September 2024
Unit of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy
Objective: Selected populations of patients with chronic hepatitis B (CHB) may benefit from a combined use of pegylated interferon-alpha (pegIFN-α) and nucleos(t)ides (NUCs). The aim of our study was to assess the immunomodulatory effect of pegIFN-α on T and natural killer (NK) cell responses in NUC-suppressed patients to identify cellular and/or serological parameters to predict better T cell-restoring effect and better control of infection in response to pegIFN-α for a tailored application of IFN-α add-on.
Design: 53 HBeAg-negative NUC-treated patients with CHB were randomised at a 1:1 ratio to receive pegIFN-α-2a for 48 weeks, or to continue NUC therapy and then followed up for at least 6 months maintaining NUCs.
The interferon story continues: EORTC CLTG study explores pegylated interferon α-2a's role in treating mycosis fungoides/Sézary syndrome.
Br J Dermatol
August 2024
University Department for Dermatology, Venerology, Allergology and Phlebology, Skin Cancer Center, Johannes Wesling Medical Center, UKRUB, University of Bochum, Minden, Germany.
Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D.
Trop Med Infect Dis
March 2024
Infectious Diseases Department, Universitatea de Medicina si Farmacie "Carol Davila", 050474 Bucuresti, Romania.
Article Synopsis
- Pegylated interferon alpha 2a is still used to treat chronic hepatitis D, showing a virologic response of 17-47% but with over 50% of patients experiencing relapses.
- In a study of 76 patients under a Romanian protocol, treatment typically lasted 48 to 96 weeks, with specific criteria for stopping and restarting based on viral load changes.
- Out of the monitored patients, 35.5% showed significant viral load reduction after 6 months, with a subset achieving undetectable levels for at least 24 weeks post-treatment, while moderate adverse reactions were common.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!